Compare DexCom, Inc. (DXCM) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Logitech International SA — how do they compare? DexCom, Inc. trades at $84 (market cap $31.86B), while Logitech International SA trades at $98.4 (market cap $14.46B). The key difference: DexCom, Inc. is far larger — about 2.2× Logitech International SA's market cap, and Logitech International SA pays a 1.63% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Logitech International SA for 92 Days on average.
| DXCM | LOGI | |
|---|---|---|
Market Cap | $31.86B | $14.46B |
Volume | 3,607,070 | 349,547 |
Sector | Health | Technology |
52-Week High | $92.34 | $126.69 |
52-Week Low | $54.84 | $85.84 |
Typical Hold Time | 62 Days | 92 Days |
Enterprise Value | $31.32B | $12.79B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Logitech (LOGI) trades at $100.70, down 1.45% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $107.00. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $1.85 surpassing the $1.26 estimate. The company maintains strong profitability, including a 16.28% net income margin and 35.29% ROE, and has announced new product launches like the Zone Vibe Pro headset and a partnership with SEGA.
The outlook is supported by solid fundamentals and positive product news, but risks include competitive pressures and macroeconomic sensitivity. Analyst sentiment is mixed, with a Hold consensus, suggesting cautious optimism. Upside potential exists if the company continues its earnings beat streak and navigates supply chain challenges effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
